![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
What Surface Protein Do CAR T-cell Therapies Target in Lymphoma?
Lymphoma CAR T-cell therapies target CD19. This is a protein present on the surface of cells of most B-cell lymphomas. Other potential targets for future CAR T-cell therapy are under investigation and may be available to you as part of a clinical trial.
|
CAR T-cell therapy |
Brand name (Company) |
Lymphoma type(s) approved for |
Targeted protein |
|
Axicabtagene ciloleucel |
Yescarta (Kite/Gilead) |
Large B-cell lymphoma, follicular lymphoma |
CD19 |
|
Brexucabtagene autoleucel |
Tecartus (Kite/Gilead) |
Mantle cell lymphoma |
CD19 |
|
Lisocabtagene maraleucel |
Breyanzi (Juno Therapeutics/Bristol Myers Squibb) |
Large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma |
CD19 |
|
Tisagenlecleucel |
Kymriah (Novartis) |
Large B-cell lymphoma, follicular lymphoma |
CD19 |